Triple-Agonist Obesity Drugs Show Weight Loss Comparable to Bariatric Surgery in Phase 3 Trials

A triple-agonist obesity medication has demonstrated weight loss outcomes similar to bariatric surgery in Phase 3 trials, marking a significant advance in anti-obesity pharmacotherapy. The drug retatrutide targets three different receptors that may be involved in obesity pathogenesis.

Research shows that GLP-1 analog medicines semaglutide, tirzepatide, and retatrutide helped reduce weight even in patients with genetic causes of obesity. The drugs were effective in patients with MC4R deficiency, suggesting they could help people with rare obesity-related gene problems.

The enhanced efficacy of newer multi-receptor drugs stems from their ability to activate multiple hormonal pathways simultaneously. Tirzepatide targets both the GLP-1 receptor and the GIP receptor, another hormone involved in metabolism. When multiple receptors expressed in different tissues or on the same cells are activated, the effects are synergistic rather than simply additive.

GLP-1 and GIP receptors are found in the brain, alongside fat cells, pancreatic beta cells and other tissues involved in metabolism. Activating both receptors can improve insulin secretion, enhance fat metabolism and amplify appetite suppression. Much of the benefit appears to come from the central nervous system, but GIP receptors are also expressed on adipocytes, which gives these drugs additional metabolic effects.

Preclinical studies show that if the action of GLP-1 drugs is restricted to the brain alone, reduced food intake still occurs. This indicates that appetite suppression is fundamentally a brain-mediated effect. The drugs essentially amplify the body's own satiety cues, strengthening natural "stop" signals rather than simply prompting patients to choose to eat less.

These medications work at more than one point in the eating process. They reduce cravings and food-seeking behavior before a meal even begins and then increase feelings of fullness once eating starts. The drugs also blunt the dopamine response normally triggered by eating, especially calorie-dense or highly palatable food. Food simply becomes less rewarding, though patients still enjoy eating.

The pace of innovation in this field is accelerating. Researchers are already testing triple-agonist drugs such as retatrutide, which target GLP-1, GIP and glucagon receptors. Early data suggest even greater weight loss and metabolic benefits. A group is now working on a five-receptor agonist as an even more ambitious approach.

Currently approved GLP-1 medications include weekly injectable semaglutide and tirzepatide, with semaglutide now also available in a daily oral formulation. The company that makes tirzepatide is pursuing an oral formulation of their own small molecule GLP-1 receptor agonist, orforglipron. Other anti-obesity medications in the drug development pipeline include a monthly injection called maritide.

For pediatric populations, only semaglutide is FDA-approved for use in children 12 and up. Its predecessor, liraglutide, is also approved for ages 12 and up, though the weight loss associated with liraglutide is far less than with semaglutide and it requires a daily injection. Data are available for the use of liraglutide in patients with obesity as young as age 6, but because its patent has expired, the company has no intention of filing for FDA approval for children that age.

Tirzepatide is currently being studied in patients ages 12 to 18, with that trial expected to be completed in 2027. Trials for children down to age 6 aren't expected to be completed until 2030. The FDA approved tirzepatide for adults in November 2023.